

Alain P Algazi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754299/publications.pdf>

Version: 2024-02-01

61
papers

15,932
citations

87723

38
h-index

133063

59
g-index

63
all docs

63
docs citations

63
times ranked

21918
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
2	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	13.9	2,445
3	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	6.3	1,153
4	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
6	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	5.1	841
7	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639
8	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	3.9	439
9	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256.	9.4	434
10	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
11	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	2.0	385
12	Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. <i>Electroencephalography and Clinical Neurophysiology</i> , 1992, 82, 356-368.	0.3	313
13	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	7.7	299
14	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
15	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
16	Overall Survival and Durable Responses in Patients With BRAF V600 Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
17	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
18	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224

#	ARTICLE	IF	CITATIONS
19	Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. <i>Electroencephalography and Clinical Neurophysiology</i> , 1992, 82, 341-355.	0.3	212
20	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473.	2.3	203
21	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
22	Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. <i>Psychophysiology</i> , 1994, 31, 469-479.	1.2	154
23	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1083-1088.	0.6	145
24	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	5.1	129
25	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3003-3003.	0.8	120
26	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	2.9	112
27	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 2827-2837.	3.2	86
28	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021, 39, 1375-1387.e6.	7.7	78
29	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	2.3	76
30	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 665-674.	1.5	73
31	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	15.2	71
32	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1910-1919.	3.2	66
33	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	0.6	66
34	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. <i>Cancer Immunology Research</i> , 2020, 8, 246-254.	1.6	61
35	Dual MEK/AKT inhibition with trametinib and <i>GSK</i> 2141795 does not yield clinical benefit in metastatic <i>NRAS</i> mutant and wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 110-114.	1.5	55
36	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020, 11, 6262.	5.8	50

#	ARTICLE	IF	CITATIONS
37	Brain potential signs of feature processing during auditory selective attention. <i>NeuroReport</i> , 1991, 2, 189-192.	0.6	48
38	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	1.0	42
39	Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	42
40	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 2010, 2, 197.	0.9	38
41	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
42	Biology and Treatment of Primary Central Nervous System Lymphoma. <i>Neurotherapeutics</i> , 2009, 6, 587-597.	2.1	35
43	Treatment modality impact on quality of life for human papillomavirusâ€“associated oropharynx cancer. <i>Laryngoscope</i> , 2020, 130, E48-E56.	1.1	30
44	A watershed year for improvements in treatment?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 76-78.	12.5	20
45	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600^{E/K} mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 603-606.	1.5	18
46	Ultraviolet lightâ€“related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. <i>Head and Neck</i> , 2019, 41, E82-E85.	0.9	17
47	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-NaÃ“ve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1157-1166.	3.2	16
48	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. <i>Clinical Cancer Research</i> , 2022, 28, 903-914.	3.2	14
49	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 781-796.	3.3	11
50	Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. <i>Molecular Cancer Research</i> , 2022, 20, 983-995.	1.5	8
51	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4122-4130.	0.7	7
52	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2578-2578.	0.8	5
53	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 174-188.	2.0	5
54	Relationship between liver metastases and PD-1 blockade in melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3072-3072.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. Journal of Clinical Oncology, 2017, 35, 78-78.	0.8	3
56	NRAS-Mutant Melanoma: Response to Chemotherapy. Archives of Dermatology, 2011, 147, 626.	1.7	1
57	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. Journal of Clinical Oncology, 2017, 35, e21594-e21594.	0.8	1
58	New horizons in melanoma treatment: targeting molecular pathways. Ochsner Journal, 2010, 10, 93-8.	0.5	1
59	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. Melanoma Management, 2017, 4, 79-82.	0.1	0
60	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. Journal of Clinical Oncology, 2017, 35, 9558-9558.	0.8	0
61	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. Journal of Clinical Oncology, 2017, 35, e21593-e21593.	0.8	0